Aventis to make India an r&d hub
Aventis Pharma is to shift a major part of its global r&d operations into India by setting up its Drug Innovation and Approval (DI&A) division in Mumbai. The DI&A arm currently operates in the US, Germany and France.
Industry sources confirmed that the company has already started the infrastructure and human resource development exercise at Aventis Pharma Limited, the Indian subsidiary of the multi-national company.
The DI&A signifies a change in the approach of identifying, developing and obtaining approvals for innovative therapeutics simultaneously in key countries.